On one hand, high mRNA and protein levels of YAP/TAZ associate with poor prognosis of patients in nonsmall-cell lung cancer, HCC, melanoma, glioma, colon cancer, and breast cancer [274]. Here, YAP1 is linked to breast carcinoma.